Roth Capital Positive on BioLineRx (BLRX) Following BL-8040 Phase 2b Initiation

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. QGEN
10. SPY

Go back to Roth Capital Positive on BioLineRx (BLRX) Following BL-8040 Phase 2b Initiation

BioLineRx (BLRX) Initiates Phase 2b Trial for BL-8040 in Treatment of AML

August 17, 2015 7:17 AM EDT

BioLineRx Ltd. (NASDAQ: BLRX) announced today the initiation of a Phase 2b trial for BL-8040 as a novel consolidation treatment for acute myeloid leukemia (AML). The Phase 2b study will examine BL-8040 as part of a second stage treatment, termed consolidation therapy, to improve outcomes for AML patients who have achieved remission after the standard initial treatment regimen, known as induction therapy. The consolidation therapy is aimed at eliminating the minimal residual disease left in the bone marrow after induction therapy that can lead to relapse. This study is the first of three clinical... More